Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF1 | Q13422 | 5/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.54 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25280863 | 1.00 | IKZF1 (0.61) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL25741174 | 0.95 | IKZF2 (0.59) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL25741173 | 0.95 | IKZF2 (0.59) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL25242491 | 0.95 | IKZF1 (0.63) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL27196345 | 0.91 | IKZF2 (0.55) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL27196342 | 0.91 | IKZF2 (0.55) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL27196356 | 0.91 | IKZF2 (0.55) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL25741260 | 0.89 | IKZF2 (0.57) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL25741266 | 0.89 | IKZF2 (0.57) | IKZF1IKZF2CRBNGSPT1DDB1 | |
| SCHEMBL23357919 | 0.89 | IKZF1 (0.59) | IKZF1IKZF2CRBNCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | IKZF1 2/4885IKZF2 1/4885CRBN 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.